Simulation Technology Start-Up Featured on the Dr. Oz Show

Wilmington, DE | October 2018 – University of Delaware (UD) licensee Avkin, a leader in wearable technology for patient centered simulation, was featured on an episode of the Dr. Oz show on October 10, 2018, along with special guest, Shark Tank’s Daymond John.  CEO Amy Cowperthwait showcased how live patient actors interact with Avkin’s wearable simulators to provide realistic simulation for training medical professionals.

RatnerPrestia Shareholders, Rex Donnelly and Andrew Koopman, working with UD’s Office of Economic Innovation and Partnerships (OEIP), drafted and are prosecuting a series of patent applications licensed to Avkin by the University, including granted U.S. Patent No. 9,721,483 for MEDICAL TREATMENT SIMULATION DEVICES.  Ms. Cowperthwait, a faculty member at UD, where she is the Director of the Interprofessional Simulation Center and Co-founder of Healthcare Theater, is one of several co-inventors on a series of patent applications relating to wearable simulators, some of which were developed as part of an Interdisciplinary Senior Design project co-sponsored by the University’s College of Engineering and the School of Nursing’s Healthcare Theatre Program.

RatnerPrestia takes great pride in helping protect the ground breaking discoveries of its clients in all facets of technology.  What We Do Together Matters™

About RatnerPrestia

RatnerPrestia is a law firm expert in all things IP. The Firm handles procurement, enforcement, licensing, commercialization, global strategic IP planning, and all related business aspects of IP. The Firm has attorneys experienced and successful in all relevant U.S. and German jurisdictions, including the U.S. Patent and Trademark Office, The German Patent Office, The European Patent Office, The U.S. International Trade Commission, and Federal Courts, both trial and appellate. This expertise extends to all areas of IP protection, including patent, design, copyright, software, trademark, and trade secret protection.